IDiyas

For the Inventor, By the Inventor

Brussels, Belgium

Pierre Van Der Bruggen

USPTO Granted Patents = 73 


Average Co-Inventor Count = 4.3

ph-index = 13

Forward Citations = 582(Granted Patents)


Inventors with similar research interests:


Location History:

  • Brussels, BE (1994 - 2013)
  • Chaumont-Gistoux, BE (2015)

Company Filing History:

goldMedal66 out of 525 
 
Ludwig Institute for Cancer Research Limited
 patents
silverMedal2 out of 446 
 
Oxford University Innovation Limited
 patents
bronzeMedal1 out of 44 
 
Johannes Gutenberg-Universität Mainz
 patents
4. 1 out of 6 
 
University of Leiden
 patents
5. 1 out of 8 
 
Leiden University
 patents
6. 1 out of 1,521 
 
Cornell Research Foundation Inc.
 patents
7. 1 out of 184 
 
Vrije Universiteit Brussel
 patents
8. 1 out of 3 
 
Ludwig Institute of Cancer Research
 patents
9. 4 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1994-2015

Loading Chart...
Loading Chart...
Areas of Expertise:
T Lymphocytes
Tumor Antigens
HLA Molecules
MAGE Peptides
Nucleic Acid Molecules
CTL Clones
Cancer Treatment
Peptide Binding
Tumor Rejection Antigens
BAGE Antigens
MHC Complexes
Cytolytic T Cells
73 patents (USPTO):Explore Patents
1. 8951747 - Method for modulating activity of T lymphocytes (2015-02-10),
2. 8349558 - Detection of individual T-cell reaction patterns against tumor-associated antigens (TAA) in tumor patients as a basis for the individual therapeutic vaccination of patients (2013-01-08),
3. 7923534 - Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3 (2011-04-12),
4. 7488793 - Isolated peptide which binds to HLA-Cw*07 and uses thereof (2009-02-10),
5. 7388072 - MAGE peptides presented by HLA class II molecules (2008-06-17),
6. 7371845 - MAGE-A3 peptides presented by HLA class II molecules (2008-05-13),
7. 7351409 - Tumor antigens and CTL clones isolated by a novel procedure (2008-04-01),
8. RE40089 - Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor (2008-02-18),
9. 7311914 - MAGE-A4 antigenic peptides and uses thereof (2007-12-25),
10. 7252825 - MAGE-3 peptides presented by HLA class II molecules (2007-08-07),
11. 7199231 - Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-4 and 41 and uses thereof (2007-04-03),
12. 7157091 - MAGE-A1 peptides presented by HLA class II molecules (2007-01-02),
13. 7049413 - MAGE-A3 peptides presented by HLA class II molecules (2006-05-23),
14. 7041502 - Isolated peptides which bind to HLA-B18 molecules and uses thereof (2006-05-09),
15. 6946289 - Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-6 and uses thereof (2005-09-20),

Title: Pierre Van Der Bruggen - A Pioneer in Cancer Immunotherapy

Introduction: Pierre Van Der Bruggen, a renowned inventor based in Brussels, BE, has made significant contributions to the field of cancer immunotherapy with a total of 73 patents to his name. His groundbreaking research focuses on modulating T lymphocyte activity and identifying target antigens for individualized therapeutic vaccinations in cancer patients.

Latest Patents: Van Der Bruggen's latest patents include a method for modulating the activity of T lymphocytes by altering the distance between key receptors on the cell surface. He has also developed a novel approach for detecting individual T-cell reaction patterns against tumor-associated antigens, paving the way for personalized tumor vaccines and therapeutics.

Career Highlights: Throughout his career, Pierre Van Der Bruggen has been associated with prestigious institutions such as the Ludwig Institute for Cancer Research Limited. His innovative work has not only led to the development of cutting-edge patents but has also advanced the field of cancer immunotherapy.

Collaborations: Van Der Bruggen has collaborated closely with esteemed researchers and colleagues, including Thierry R Boon-Falleur and Catia Traversari. Together, they have shared expertise and knowledge to drive forward groundbreaking research in cancer immunotherapy.

Conclusion: In conclusion, Pierre Van Der Bruggen's pioneering work in cancer immunotherapy underscores his commitment to revolutionizing patient care through personalized treatment strategies. His passion for innovation and dedication to improving outcomes for cancer patients have cemented his status as a key figure in the field of medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…